A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles

Liang Pang, Chun Zhang, Jing Qin, Limei Han, Ruixiang Li, Chao Hong, Huining He, Jianxin WangDrug 2017 · DOI

TL;DR

This review explores the exciting frontier of using living cells as "Trojan horses" to deliver nanoparticles (NPs) and therapeutic agents to specific disease sites. By combining the targeting capabilities of cells with the versatility of NPs, this approach promises to overcome limitations of traditional drug delivery, leading to improved efficacy and reduced side effects.

What Problem Does This Paper Address?

Many promising therapeutic agents, including small molecules, peptides, and proteins, face significant hurdles in clinical application. These challenges include poor solubility, short circulation times in the body, and off-target toxicity leading to serious side effects. While nanotechnology has offered solutions through nanoparticles (NPs) designed for controlled release and targeted delivery, these systems often struggle with complete avoidance of the reticuloendothelial system (RES) uptake and achieving sufficient targeting efficiency. This paper addresses the need for more sophisticated drug delivery strategies that can overcome these limitations by leveraging the inherent biological functions of living cells.

Methods

This review focuses on a strategy that combines the advantages of both cell-based carriers and nanoparticle technology. The core idea is to load therapeutic agents, often encapsulated within nanoparticles, into specific types of cells. These "cell-NP hybrids" then utilize the natural homing and migration capabilities of the chosen cell to reach diseased tissues. The paper discusses two primary methods for attaching NPs to cells:

  • Non-covalent Coupling: This involves simply mixing NPs with cells, allowing them to adhere via weak interactions like van der Waals forces, electrostatic forces, hydrogen bonding, and hydrophobic forces. This method is simple and preserves cell function but can be fragile, leading to NP detachment in vivo due to shear stress.
  • Covalent Coupling: This method involves chemically modifying either the NP or the cell surface to create a stable, covalent bond. This is achieved by exploiting functional groups on cell surfaces (e.g., thiol, amine, sialic acid) and using reactive groups on NPs (e.g., maleimide). This approach offers stronger adhesion but can be more complex and potentially impact cell function.

The paper also touches upon NP internalization by cells (e.g., phagocytosis by leukocytes) as another way to achieve cell-mediated delivery.

Datasets

Not discussed in the paper. This is a review article summarizing existing research and does not present new experimental data or datasets.

Key Insights and Ideas

  • Cells as "Trojan Horses": The fundamental concept of using cells to shield and transport drugs/NPs into the body is a powerful analogy. Cells can act as natural carriers, mimicking their own migration patterns to reach specific tissues.
  • Synergy of Cells and NPs: The combination is key. NPs offer tunable properties (size, surface charge, targeting ligands), while cells provide inherent targeting, prolonged circulation, and the ability to navigate complex biological environments.
  • Red Blood Cells (RBCs) as Accessible Carriers: RBCs are abundant, readily available, and have a long lifespan, making them attractive for drug reservoirs and sustained release. However, modifications can sometimes alter their function and lead to RES uptake.
  • Leukocytes for Targeted Inflammation and Tumor Delivery: Leukocytes, particularly macrophages and T cells, possess a natural tropism for sites of inflammation and tumors. Their ability to infiltrate tissues and even cross the blood-brain barrier makes them ideal for delivering therapeutics to these challenging locations.
  • Stem Cells for Regeneration and Targeted Delivery: Stem cells offer the dual benefit of regenerative potential and homing to injured or diseased sites. They can be engineered to enhance their targeting capabilities and deliver NPs for imaging or therapy.
  • Exosomes as Natural Nanocarriers: Beyond whole cells, cell-derived vesicles like exosomes are emerging as natural, biocompatible carriers that can deliver therapeutic payloads and mimic cell-to-cell communication.

Key Results

This review does not present specific quantitative results from new experiments. Instead, it highlights findings from previously published studies:

  • RBCs with LMWP-mediated encapsulation: Demonstrated a prolonged plasma half-life of approximately 9.2 days for encapsulated asparaginase, compared to 5.9 days for hypotonic methods, leading to significantly increased survival time in mice.
  • Leukocyte-delivered nanozymes: In a Parkinson's disease model, nanozymes loaded into macrophages showed significantly increased accumulation in the brain and longer retention (up to 48 hours) compared to free nanozymes (cleared within 2 hours).
  • MSC-NP systems for brain tumors: Mesenchymal stem cells (MSCs) engineered with hyaluronic acid-coated mesoporous silica nanoparticles (HA-MSN-64Cu) showed a 5.2 ± 1.3-fold higher tumor accumulation in gliomas compared to free HA-MSN-64Cu.
  • RBC-membrane-camouflaged NPs: These systems demonstrated successful prevention of RES uptake, long circulatory half-lives, and reduced side effects compared to traditional PEGylated NPs.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • In Vitro vs. In Vivo: Most studies are currently performed in vitro or in animal models. More extensive research is needed in human trials to assess safety and efficacy.
  • Safety and Risk Assessment: The safety of these cell-based delivery systems for patients needs thorough evaluation, considering potential risks and benefits.
  • Storage and Contamination: Challenges related to storing and preventing contamination of autologous cell carriers remain significant.
  • Industrial Standardization: A recognized industrial procedure for preparing these cell-NP carriers is currently lacking.
  • NP Detachment: For non-covalent coupling, improving the stability of NP attachment to cells and ensuring controlled detachment at the target site is crucial.
  • Stimulus-Responsive Systems: Developing systems where NPs can detach from cells under specific environmental stimuli (e.g., pH, enzymes) at the diseased site is an area for future research.
  • Combinational Therapy: Exploring the potential of combining cell-NP delivery with other therapeutic modalities.
  • Exosome Engineering: Further development of exosome-based delivery systems, including methods for efficient loading and targeting.

Summary updated

Abstract

Cell-mediated drug delivery systems employ specific cells as drug vehicles to deliver drugs to targeted sites. Therapeutics or imaging agents are loaded into these cells and then released in diseased sites. These specific cells mainly include red blood cells, leukocytes, stem cells and so on. The cell acts as a Trojan horse to transfer the drug from circulating blood to the diseased tissue. In such a system, these cells keep their original properties, which allow them to mimic the migration behavior of specific cells to carry drug to the targeted site after in vivo administration. This strategy elegantly combines the advantages of both carriers, i.e. the adjustability of nanoparticles (NPs) and the natural functions of active cells, which therefore provides a new perspective to challenge current obstacles in drug delivery. This review will describe a fundamental understanding of these cell-based drug delivery systems, and discuss the great potential of combinational application of cell carrier and NPs.
BibTeX
@inproceedings{pang2017novel,
  author = {Liang Pang and Chun Zhang and Jing Qin and Limei Han and Ruixiang Li and Chao Hong and Huining He and Jianxin Wang},
  title = {{A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles}},
  booktitle = {Drug},
  year = {2017},
  doi = {10.1080/10717544.2016.1230903},
}
Figure